Maze Therapeutics

MAZEPhase 2

Maze Therapeutics is a biotechnology company that maps the connections between genetic variants and disease to develop novel therapeutics. The company's core Compass platform integrates human genetics, functional genomics, and data science to identify protective genetic modifiers, which serve as blueprints for drug development. Maze has advanced its lead candidate, MZE001 for APOL1-mediated kidney disease, into Phase 2 clinical trials and secured significant funding, including a $190 million Series C and a strategic partnership with Sanofi. The company aims to build a pipeline of precision medicines for patients with high unmet need.

Market Cap

$2.3B

Employees

100-200

Focus

Biotech

MAZE · Stock Price

USD 48.03+32.08 (+201.13%)

Historical price data

AI Company Overview

Technology Platform

The Compass Platform integrates human genetics, functional genomics, and data science to identify protective genetic modifiers of disease, which are then used as blueprints for developing small molecule therapeutics.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
MZE829	Proteinuric Kidney Disease	Phase 2
MZE001 + Placebo	Healthy	Phase 1

Funding History

Total raised: $326M

Series B$135MCasdin CapitalJan 1, 2021

Series A$191MThird Rock VenturesJan 1, 2020

Opportunities

Maze has a major opportunity to establish the first approved therapy for APOL1-mediated kidney disease, a large and untreated market.

Its Compass platform provides a validated engine for discovering new programs across multiple disease areas, enabling sustainable pipeline growth.

Strategic partnerships, like the one with Sanofi, offer significant non-dilutive funding and validation.

Risk Factors

The company faces significant clinical risk with its lead asset, MZE001, currently in Phase 2.

It operates in a competitive AMKD landscape with larger players like Vertex.

The long-term validation of its genetics-driven platform depends on translating multiple discoveries into successful clinical candidates.

Competitive Landscape

In APOL1-mediated kidney disease, Maze competes directly with Vertex Pharmaceuticals (Phase 3) and Novartis. Its differentiation lies in MZE001's specific mechanism. More broadly, its genetics-driven discovery platform competes with other biotechs leveraging human genetics, but its focus on protective modifiers and integrated small molecule development is a key distinction.

Publications

Patents

Pipeline